Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data

benzinga.com/news/health-care/25/08/46853379/exclusive-vivani-prioritizes-semaglutide-based-implant-after-promising-preclinical-data

Vivani Medical Inc. (NASDAQ:VANI) on Tuesday reported results from the LIBERATE-1 Phase 1 study of the exenatide GLP-1 implant NPM-115, representing the first-in-human test of the company's proprietary NanoPortal implant technology.
Exenatide is sold by AstraZeneca Plc (NASDAQ:AZN) under…

This story appeared on benzinga.com, 2025-08-05 11:32:09.
The Entire Business World on a Single Page. Free to Use →